Susquehanna International Group’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-19,600
| Closed | -$257K | – | 13136 |
|
|
2025
Q4 | $257K | Sell |
19,600
-31,200
| -61% | -$373K | ﹤0.01% | 10310 |
|
|
2025
Q3 | $370K | Buy |
+50,800
| New | +$344K | ﹤0.01% | 9642 |
|
|
2024
Q2 | – | Sell |
-14,700
| Closed | -$207K | – | 12007 |
|
|
2024
Q1 | $207K | Buy |
+14,700
| New | +$183K | ﹤0.01% | 10529 |
|
|
2023
Q3 | – | Sell |
-11,300
| Closed | -$94.1K | – | 11985 |
|
|
2023
Q2 | $94.1K | Buy |
+11,300
| New | +$130K | ﹤0.01% | 10995 |
|
|
2022
Q2 | – | Sell |
-216,300
| Closed | -$1.45M | – | 12839 |
|
|
2022
Q1 | $1.45M | Buy |
216,300
+158,800
| +276% | +$946K | ﹤0.01% | 6220 |
|
|
2021
Q4 | $310K | Buy |
57,500
+17,500
| +44% | +$115K | ﹤0.01% | 10417 |
|
|
2021
Q3 | $354K | Buy |
40,000
+36,233
| +962% | +$347K | ﹤0.01% | 10218 |
|
|
2021
Q2 | $48K | Sell |
3,767
-29,833
| -89% | -$387K | ﹤0.01% | 12307 |
|
|
2021
Q1 | $583K | Buy |
33,600
+25,233
| +302% | +$456K | ﹤0.01% | 9131 |
|
|
2020
Q4 | $107K | Buy |
+8,367
| New | +$149K | ﹤0.01% | 10464 |
|
Susquehanna International Group's ATXS Position: Q1 2026 in Review
Susquehanna International Group sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 36,322 shares — an estimated $475K sold.
Susquehanna International Group first reported a position in ATXS in Q3 2015 and held it in 17 quarters. The position peaked at $2.92M in Q1 2023. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Susquehanna International Group reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Susquehanna International Group sold 36,322 Astria Therapeutics shares in Q1 2026, an estimated $475K.
- Susquehanna International Group first reported a position in Astria Therapeutics in Q3 2015 and held it in 17 quarters.
- Susquehanna International Group's Astria Therapeutics position peaked at $2.92M in Q1 2023.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.